The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global GLP-1 Peptide Drugs Market Research Report 2025
Synopsis
Glucagon-likepeptide-1 (GLP-1) is a hormone secreted by intestinal L cells. Its receptor (GLP-1R) is widely distributed in the central nervous system, cardiovascular system, muscles, and gastrointestinal tract. multiple organs and tissues. GLP-1 has glucose concentration-dependent hypoglycemic effects, and its receptor agonist (GLP-1RA) can simulate the physiological effects of GLP-1 and is an important drug for the treatment of diabetes and obesity. In addition, GLP-1RA also has protective effects on the cardiovascular system, kidneys, central nervous system, etc.
GLP-1 peptide drugs are often used to treat patients with type 2 diabetes. They can control blood sugar while also bringing weight loss and reducing cardiovascular risk.
The global GLP-1 Peptide Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for GLP-1 Peptide Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for GLP-1 Peptide Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for GLP-1 Peptide Drugs in Type 2 Diabetes is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of GLP-1 Peptide Drugs include AstraZeneca, Novo Nordisk, Sanofi, GSK, Eli Lilly, Benemae Pharmaceutical, Hansoh Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for GLP-1 Peptide Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding GLP-1 Peptide Drugs.
The GLP-1 Peptide Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global GLP-1 Peptide Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the GLP-1 Peptide Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
Novo Nordisk
Sanofi
GSK
Eli Lilly
Benemae Pharmaceutical
Hansoh Pharmaceutical
Segment by Type
Injection
Oral
Segment by Application
Type 2 Diabetes
Obesity
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of GLP-1 Peptide Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Glucagon-likepeptide-1 (GLP-1) is a hormone secreted by intestinal L cells. Its receptor (GLP-1R) is widely distributed in the central nervous system, cardiovascular system, muscles, and gastrointestinal tract. multiple organs and tissues. GLP-1 has glucose concentration-dependent hypoglycemic effects, and its receptor agonist (GLP-1RA) can simulate the physiological effects of GLP-1 and is an important drug for the treatment of diabetes and obesity. In addition, GLP-1RA also has protective effects on the cardiovascular system, kidneys, central nervous system, etc.
GLP-1 peptide drugs are often used to treat patients with type 2 diabetes. They can control blood sugar while also bringing weight loss and reducing cardiovascular risk.
The global GLP-1 Peptide Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for GLP-1 Peptide Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for GLP-1 Peptide Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for GLP-1 Peptide Drugs in Type 2 Diabetes is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of GLP-1 Peptide Drugs include AstraZeneca, Novo Nordisk, Sanofi, GSK, Eli Lilly, Benemae Pharmaceutical, Hansoh Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for GLP-1 Peptide Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding GLP-1 Peptide Drugs.
The GLP-1 Peptide Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global GLP-1 Peptide Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the GLP-1 Peptide Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
Novo Nordisk
Sanofi
GSK
Eli Lilly
Benemae Pharmaceutical
Hansoh Pharmaceutical
Segment by Type
Injection
Oral
Segment by Application
Type 2 Diabetes
Obesity
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of GLP-1 Peptide Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global GLP-1 Peptide Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Injection
1.2.3 Oral
1.3 Market by Application
1.3.1 Global GLP-1 Peptide Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Type 2 Diabetes
1.3.3 Obesity
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global GLP-1 Peptide Drugs Market Perspective (2019-2030)
2.2 Global GLP-1 Peptide Drugs Growth Trends by Region
2.2.1 Global GLP-1 Peptide Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 GLP-1 Peptide Drugs Historic Market Size by Region (2019-2024)
2.2.3 GLP-1 Peptide Drugs Forecasted Market Size by Region (2025-2030)
2.3 GLP-1 Peptide Drugs Market Dynamics
2.3.1 GLP-1 Peptide Drugs Industry Trends
2.3.2 GLP-1 Peptide Drugs Market Drivers
2.3.3 GLP-1 Peptide Drugs Market Challenges
2.3.4 GLP-1 Peptide Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top GLP-1 Peptide Drugs Players by Revenue
3.1.1 Global Top GLP-1 Peptide Drugs Players by Revenue (2019-2024)
3.1.2 Global GLP-1 Peptide Drugs Revenue Market Share by Players (2019-2024)
3.2 Global GLP-1 Peptide Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by GLP-1 Peptide Drugs Revenue
3.4 Global GLP-1 Peptide Drugs Market Concentration Ratio
3.4.1 Global GLP-1 Peptide Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by GLP-1 Peptide Drugs Revenue in 2023
3.5 Global Key Players of GLP-1 Peptide Drugs Head office and Area Served
3.6 Global Key Players of GLP-1 Peptide Drugs, Product and Application
3.7 Global Key Players of GLP-1 Peptide Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 GLP-1 Peptide Drugs Breakdown Data by Type
4.1 Global GLP-1 Peptide Drugs Historic Market Size by Type (2019-2024)
4.2 Global GLP-1 Peptide Drugs Forecasted Market Size by Type (2025-2030)
5 GLP-1 Peptide Drugs Breakdown Data by Application
5.1 Global GLP-1 Peptide Drugs Historic Market Size by Application (2019-2024)
5.2 Global GLP-1 Peptide Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America GLP-1 Peptide Drugs Market Size (2019-2030)
6.2 North America GLP-1 Peptide Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America GLP-1 Peptide Drugs Market Size by Country (2019-2024)
6.4 North America GLP-1 Peptide Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe GLP-1 Peptide Drugs Market Size (2019-2030)
7.2 Europe GLP-1 Peptide Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe GLP-1 Peptide Drugs Market Size by Country (2019-2024)
7.4 Europe GLP-1 Peptide Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific GLP-1 Peptide Drugs Market Size (2019-2030)
8.2 Asia-Pacific GLP-1 Peptide Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific GLP-1 Peptide Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific GLP-1 Peptide Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America GLP-1 Peptide Drugs Market Size (2019-2030)
9.2 Latin America GLP-1 Peptide Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America GLP-1 Peptide Drugs Market Size by Country (2019-2024)
9.4 Latin America GLP-1 Peptide Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa GLP-1 Peptide Drugs Market Size (2019-2030)
10.2 Middle East & Africa GLP-1 Peptide Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa GLP-1 Peptide Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa GLP-1 Peptide Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Details
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca GLP-1 Peptide Drugs Introduction
11.1.4 AstraZeneca Revenue in GLP-1 Peptide Drugs Business (2019-2024)
11.1.5 AstraZeneca Recent Development
11.2 Novo Nordisk
11.2.1 Novo Nordisk Company Details
11.2.2 Novo Nordisk Business Overview
11.2.3 Novo Nordisk GLP-1 Peptide Drugs Introduction
11.2.4 Novo Nordisk Revenue in GLP-1 Peptide Drugs Business (2019-2024)
11.2.5 Novo Nordisk Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Details
11.3.2 Sanofi Business Overview
11.3.3 Sanofi GLP-1 Peptide Drugs Introduction
11.3.4 Sanofi Revenue in GLP-1 Peptide Drugs Business (2019-2024)
11.3.5 Sanofi Recent Development
11.4 GSK
11.4.1 GSK Company Details
11.4.2 GSK Business Overview
11.4.3 GSK GLP-1 Peptide Drugs Introduction
11.4.4 GSK Revenue in GLP-1 Peptide Drugs Business (2019-2024)
11.4.5 GSK Recent Development
11.5 Eli Lilly
11.5.1 Eli Lilly Company Details
11.5.2 Eli Lilly Business Overview
11.5.3 Eli Lilly GLP-1 Peptide Drugs Introduction
11.5.4 Eli Lilly Revenue in GLP-1 Peptide Drugs Business (2019-2024)
11.5.5 Eli Lilly Recent Development
11.6 Benemae Pharmaceutical
11.6.1 Benemae Pharmaceutical Company Details
11.6.2 Benemae Pharmaceutical Business Overview
11.6.3 Benemae Pharmaceutical GLP-1 Peptide Drugs Introduction
11.6.4 Benemae Pharmaceutical Revenue in GLP-1 Peptide Drugs Business (2019-2024)
11.6.5 Benemae Pharmaceutical Recent Development
11.7 Hansoh Pharmaceutical
11.7.1 Hansoh Pharmaceutical Company Details
11.7.2 Hansoh Pharmaceutical Business Overview
11.7.3 Hansoh Pharmaceutical GLP-1 Peptide Drugs Introduction
11.7.4 Hansoh Pharmaceutical Revenue in GLP-1 Peptide Drugs Business (2019-2024)
11.7.5 Hansoh Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of TablesList of Tables
Table 1. Global GLP-1 Peptide Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Injection
Table 3. Key Players of Oral
Table 4. Global GLP-1 Peptide Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global GLP-1 Peptide Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global GLP-1 Peptide Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global GLP-1 Peptide Drugs Market Share by Region (2019-2024)
Table 8. Global GLP-1 Peptide Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global GLP-1 Peptide Drugs Market Share by Region (2025-2030)
Table 10. GLP-1 Peptide Drugs Market Trends
Table 11. GLP-1 Peptide Drugs Market Drivers
Table 12. GLP-1 Peptide Drugs Market Challenges
Table 13. GLP-1 Peptide Drugs Market Restraints
Table 14. Global GLP-1 Peptide Drugs Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global GLP-1 Peptide Drugs Market Share by Players (2019-2024)
Table 16. Global Top GLP-1 Peptide Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in GLP-1 Peptide Drugs as of 2023)
Table 17. Ranking of Global Top GLP-1 Peptide Drugs Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by GLP-1 Peptide Drugs Revenue (CR5 and HHI) & (2019-2024)
Table 19. Global Key Players of GLP-1 Peptide Drugs, Headquarters and Area Served
Table 20. Global Key Players of GLP-1 Peptide Drugs, Product and Application
Table 21. Global Key Players of GLP-1 Peptide Drugs, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global GLP-1 Peptide Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global GLP-1 Peptide Drugs Revenue Market Share by Type (2019-2024)
Table 25. Global GLP-1 Peptide Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global GLP-1 Peptide Drugs Revenue Market Share by Type (2025-2030)
Table 27. Global GLP-1 Peptide Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global GLP-1 Peptide Drugs Revenue Market Share by Application (2019-2024)
Table 29. Global GLP-1 Peptide Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global GLP-1 Peptide Drugs Revenue Market Share by Application (2025-2030)
Table 31. North America GLP-1 Peptide Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America GLP-1 Peptide Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America GLP-1 Peptide Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe GLP-1 Peptide Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe GLP-1 Peptide Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe GLP-1 Peptide Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific GLP-1 Peptide Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific GLP-1 Peptide Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific GLP-1 Peptide Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America GLP-1 Peptide Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America GLP-1 Peptide Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America GLP-1 Peptide Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa GLP-1 Peptide Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa GLP-1 Peptide Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa GLP-1 Peptide Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 46. AstraZeneca Company Details
Table 47. AstraZeneca Business Overview
Table 48. AstraZeneca GLP-1 Peptide Drugs Product
Table 49. AstraZeneca Revenue in GLP-1 Peptide Drugs Business (2019-2024) & (US$ Million)
Table 50. AstraZeneca Recent Development
Table 51. Novo Nordisk Company Details
Table 52. Novo Nordisk Business Overview
Table 53. Novo Nordisk GLP-1 Peptide Drugs Product
Table 54. Novo Nordisk Revenue in GLP-1 Peptide Drugs Business (2019-2024) & (US$ Million)
Table 55. Novo Nordisk Recent Development
Table 56. Sanofi Company Details
Table 57. Sanofi Business Overview
Table 58. Sanofi GLP-1 Peptide Drugs Product
Table 59. Sanofi Revenue in GLP-1 Peptide Drugs Business (2019-2024) & (US$ Million)
Table 60. Sanofi Recent Development
Table 61. GSK Company Details
Table 62. GSK Business Overview
Table 63. GSK GLP-1 Peptide Drugs Product
Table 64. GSK Revenue in GLP-1 Peptide Drugs Business (2019-2024) & (US$ Million)
Table 65. GSK Recent Development
Table 66. Eli Lilly Company Details
Table 67. Eli Lilly Business Overview
Table 68. Eli Lilly GLP-1 Peptide Drugs Product
Table 69. Eli Lilly Revenue in GLP-1 Peptide Drugs Business (2019-2024) & (US$ Million)
Table 70. Eli Lilly Recent Development
Table 71. Benemae Pharmaceutical Company Details
Table 72. Benemae Pharmaceutical Business Overview
Table 73. Benemae Pharmaceutical GLP-1 Peptide Drugs Product
Table 74. Benemae Pharmaceutical Revenue in GLP-1 Peptide Drugs Business (2019-2024) & (US$ Million)
Table 75. Benemae Pharmaceutical Recent Development
Table 76. Hansoh Pharmaceutical Company Details
Table 77. Hansoh Pharmaceutical Business Overview
Table 78. Hansoh Pharmaceutical GLP-1 Peptide Drugs Product
Table 79. Hansoh Pharmaceutical Revenue in GLP-1 Peptide Drugs Business (2019-2024) & (US$ Million)
Table 80. Hansoh Pharmaceutical Recent Development
Table 81. Research Programs/Design for This Report
Table 82. Key Data Information from Secondary Sources
Table 83. Key Data Information from Primary Sources
Table 84. Authors List of This Report
List of Figures
Figure 1. GLP-1 Peptide Drugs Picture
Figure 2. Global GLP-1 Peptide Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global GLP-1 Peptide Drugs Market Share by Type: 2023 VS 2030
Figure 4. Injection Features
Figure 5. Oral Features
Figure 6. Global GLP-1 Peptide Drugs Market Size by Application (2024-2030) & (US$ Million)
Figure 7. Global GLP-1 Peptide Drugs Market Share by Application: 2023 VS 2030
Figure 8. Type 2 Diabetes Case Studies
Figure 9. Obesity Case Studies
Figure 10. Others Case Studies
Figure 11. GLP-1 Peptide Drugs Report Years Considered
Figure 12. Global GLP-1 Peptide Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global GLP-1 Peptide Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global GLP-1 Peptide Drugs Market Share by Region: 2023 VS 2030
Figure 15. Global GLP-1 Peptide Drugs Market Share by Players in 2023
Figure 16. Global Top GLP-1 Peptide Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in GLP-1 Peptide Drugs as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by GLP-1 Peptide Drugs Revenue in 2023
Figure 18. North America GLP-1 Peptide Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America GLP-1 Peptide Drugs Market Share by Country (2019-2030)
Figure 20. United States GLP-1 Peptide Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada GLP-1 Peptide Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe GLP-1 Peptide Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe GLP-1 Peptide Drugs Market Share by Country (2019-2030)
Figure 24. Germany GLP-1 Peptide Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France GLP-1 Peptide Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. GLP-1 Peptide Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy GLP-1 Peptide Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia GLP-1 Peptide Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries GLP-1 Peptide Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific GLP-1 Peptide Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific GLP-1 Peptide Drugs Market Share by Region (2019-2030)
Figure 32. China GLP-1 Peptide Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan GLP-1 Peptide Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea GLP-1 Peptide Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia GLP-1 Peptide Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India GLP-1 Peptide Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia GLP-1 Peptide Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America GLP-1 Peptide Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America GLP-1 Peptide Drugs Market Share by Country (2019-2030)
Figure 40. Mexico GLP-1 Peptide Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil GLP-1 Peptide Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa GLP-1 Peptide Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa GLP-1 Peptide Drugs Market Share by Country (2019-2030)
Figure 44. Turkey GLP-1 Peptide Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia GLP-1 Peptide Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. UAE GLP-1 Peptide Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. AstraZeneca Revenue Growth Rate in GLP-1 Peptide Drugs Business (2019-2024)
Figure 48. Novo Nordisk Revenue Growth Rate in GLP-1 Peptide Drugs Business (2019-2024)
Figure 49. Sanofi Revenue Growth Rate in GLP-1 Peptide Drugs Business (2019-2024)
Figure 50. GSK Revenue Growth Rate in GLP-1 Peptide Drugs Business (2019-2024)
Figure 51. Eli Lilly Revenue Growth Rate in GLP-1 Peptide Drugs Business (2019-2024)
Figure 52. Benemae Pharmaceutical Revenue Growth Rate in GLP-1 Peptide Drugs Business (2019-2024)
Figure 53. Hansoh Pharmaceutical Revenue Growth Rate in GLP-1 Peptide Drugs Business (2019-2024)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
